Manuscripts

Click the category for manuscript reference details:

Population

Agustí A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.

Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184-92.

Albert P, Agustí A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-8.

Agustí A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the GOLD 2011 COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636-46.

Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376-84.

Hanson C, Sayles H, Rutten EEPA, et al. The association between dietary intake and phenotypical characteristics of COPD in the ECLIPSE cohort. Chronic Obstr Pulm Dis. 2014;1(1):115-24.

Hersh CP, Make BJ, Lynch DA, et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med. 2014;14(1):164.

Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697-700.

Rutten EPA, Spruit MA, McDonald M-LN, et al. Continuous fat-free mass decline in COPD: fact or fiction? Eur Respir J. 2015;46(5):1496-8.

Health Status (SGRQ/FACIT/CES-D)

Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604-11.

Al-Shair K, Muellerova H, Yorke J, et al. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012;10:100.

Gietema HA, Edwards LD, Coxson HO, et al. Impact of emphysema and airway wall thickening on quality of life in smoking-related COPD. Respir Med. 2013;107(8):1201-9.

Janssen DJA, Mullerova H, Agustí A, et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med. 2014;108:1647-54.

Agustí A, Rennard S, Edwards LD, et al. Clinical and prognostic heterogeneity of C and D GOLD groups. Eur Respir J. 2015;46:250-4.

Wilke S, Jones PW, Müllerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70:420-5.

Yohannes AM, Müllerova H, Hanania N, et al. Persistence of depressive symptoms in patients with COPD: A 3-year longitudinal follow-up analysis of the ECLIPSE study cohort. Chest. 2014;146:33A. doi:10.1378/chest.1978679.

Exacerbations

Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Eng J Med. 2010;363(12):1128-38.

Crim C, Celli B, Edwards L, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med. 2011;105(7):1069-78.

Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013;14:79.

Benson VS, Muellerova H, Vestbo J, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of COPD. Respir Med. 2015;109:1147-54.

Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of chronic obstructive pulmonary disease: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147:999-1007.

Exercise Tolerance and Activity

Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104(6):849-57.

Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med. 2012;187(4):382-6.

Spruit MA, Polkey MI, Celli B, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3):291-7.

Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106(4):522-30.

Polkey MI, Spruit MA, Edwards LD, et al. Reply: Minimal or maximal clinically important difference: Using death to define MCID. Am J Respir Crit Care Med. 2013;187(12):1392.

Sumner H, Woodcock A, Kolsum U, et al. Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(9):943-9.

Andrianopolous V, Wouters EFM, Pinto-Planta V, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir Med. 2015;109:1138-46.

Genomics

Cho MH, Boutaoui N, Klanderman BA, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42(3):200-2.

Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2010;44(3):316-22.

Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(12):1498-505.

Wan ES, Cho MH, Boutaoui N, et al. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2010;45(2):304-10.

Brehm JA, Hagiwara LK, Tesfaigzi Y, et al. Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease. Thorax. 2011;66(12):1085-90.

Castaldi PJ, Cho MH, Litonjua AA, et al. The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol. 2011;45(6):1147-53.

Kong X, Cho MH, Anderson WH, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med. 2011;183(1):43-9.

Lipman P, Cho M, Bakke P, et al. On the follow-up of genome-wide association studies: an overall test for the most promising SNPs. Genet Epidemiol. 2011;35(5):303-09.

Qiu W, Cho MH, Riley JH, et al. Genetics of sputum gene expression in chronic obstructive pulmonary disease. PLoS One. 2011;6(9):e24395.

Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66(6):489-95.

Aminuddin F, Akhabir L, Stefanowicz D, et al. Genetic association between human chitinases and lung function in COPD. Hum Genet. 2012;131(7):1105-14.

Cho MH, Castaldi PJ, Wan ES, et al. A genome-wide association study in COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet. 2012;21(4):947-57.

Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(12):1238-47.

Wilk JB, Shrine NR, Loehr LR, et al. Genome wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med. 2012;186(7):622-32.

Aminuddin F, Hackett TL, Stefanowicz D, et al. Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease. BMC Pulm Med. 2013;13(1):64.

Hansel NN, Ruczinski I, Rafaels N, et al. Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. Hum Genet. 2013;132(1):79-90.

Siedlinski M, Tingley D, Lipman PJ, et al. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet. 2013;132(4):431-41.

Zhou X, Qiu W, Sathirapongsasutil JF, et al. Gene expression analysis uncovers novel Hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells. Genomics. 2013;101(5):263-72.

Cho M, McDonald ML, Mattheisen M, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. The Lancet Respiratory Medicine. 2014;2(3):214-25.

Glass K, Quackenbush J, Silverman EK, et al. Sexually-dimorphic targeting of functionally-related genes in COPD. BMC Syst Biol. 2014;8(1):118.

Menche J, Sharma A, Cho MH, et al. A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in chronic obstructive pulmonary disease. BMC Syst Biol. 2014;8(Suppl 2):S8.

McDonald M-L, Cho M, Sorheim I-C, et al. Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2014;51(5):678-87.

McDonald ML, Mattheisen M, Cho MH, et al. Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks. Hum Hered. 2014;78(3):131-9.

Singh D, Fox SM, Tal-Singer R, et al. Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE Cohort. PLoS ONE. 2014;29(9):e107381.

Castaldi PJ, Cho MH, Zhou X, et al. Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Hum Mol Genet. 2015;24(4):1200-10.

Dijksta AE, Boezen HM, van den Berge M, et al. Dissecting genetic risk factors for chronic mucus hypersecretion in heavy smokers with and without COPD. Eur Respir J. 2015;45(1):60-75.

Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2015;52(3):365-76.

Imaging

Basanta M, Jarvis RM, Xu Y, et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst. 2010;135(2):315-20.

Gietema HA, Müller NL, Fauerbach PV, et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol. 2011;18(6):661-71.

Coxson H, Dirksen A, Edwards L, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013;1(2):129-36.

Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res. 2013;28(6):1369-77.

McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomographic measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease: a cross-sectional study. Ann Am Thorac Soc. 2014;11(3):326-34.

Cho MH, Castaldi PJ, Hersh CP, et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. Am J Respir Crit Care Med. 2015;192:559-69.

Thomsen LH, Shaker SB, Dirksen A, et al. Correlation between emphysema and lung function in healthy smokers and smokers with COPD. J COPD F. 2015;2(3):204-13.

Biomarkers

Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12);1058-63.

Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95-102.

Singh D, Edwards L, Tal-Singer R, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77.

Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.

Duvoix A, Miranda E, Perez J, et al. Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD. COPD. 2011;8(2):79-95.

Esther CR Jr, Lazaar AL, Bordonali E, et al. Elevated airway purines in COPD. Chest. 2011;140(4):954-60.

MacNee W, Rennard SI, Hunt JF, et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir Med. 2011;105(7):1037-45.

Sin DD, Miller B, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2011;183(9):1187-92.

Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.

Breyer MK, Rutten E, Locantore N, et al. Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. Eur J Clin Invest. 2012;42(9):983-91.

Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065-72. 

Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125-33.

Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40(2):345-55.

Berg I, Hanson C, Sayles H, et al. Vitamin D, Vitamin D Binding Protein, Lung Function and Structure in COPD. Respir Med. 2013;107(10):1578-88.

Cheng D, Kim D, Cockayne D, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(8):948-5.

Lazaar AL, Miller BE, Francombe G, et al. No TWEAK for COPD. Eur Respir J. 2013;42:1142-44.

Rutten EPA, Calverley PMA, Casuburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary disease; do they influence patient related outcomes? Ann Nutr Metab. 2013;63(3):239-47.

Diaz AA, Zhou L, Young TP, et al. Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. Acad Radiol. 2014;21(10):1255-61.

Johansson SL, Roberts NB, Schlosser A, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir Med. 2014;108(9):1336-44.

Lee JH, Cho MH, Hersh CP, et al. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2014;52:365-76.

Lee JH, McDonald M-LN, Cho MH, et al. DNAH5 is associated with total lung capacity in chronic obstructive pulmonary disease. Resp Res. 2014;15(1):97.

Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6);1697-700.

Wells JM, O'Reilly PJ, Szul T, et al. An aberrant leukotriene A4 hydrolase–proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):51-61.

Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with morbidity and mortality. Thorax. 2014;69(8):718-23.

Protocol

Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869-73.

Reviews

Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 2014;69(7):666-72.

Vestbo J, Agusti A, Wouters EFM, et al. Should we view COPD differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189(9):1022-30.

Systems Biology

Chu J-H, Hersh C, Castaldi P, et al. Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Syst Biol. 2014;8(1):78.

Rennard SI, Locantore N, Delafont B, et al. Identification of five COPD subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303-12.